Zydus gets U.S. FDA nod for Diltiazem Hydrochloride tablets
A generic of Cardizem Tablets, the drug is indicated for management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride tablets had annual sales of $13.9 million in the U.S., Zydus said, citing IQVIA MAT June 2025 numbers.
The approved drug will be produced at its plant in Baddi, Himachal Pradesh, the company said. Belonging to a class of drugs called calcium-channel blockers, Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle, it said.
Zydus Lifesciences shares closed 2.18% higher at ₹955.90 apiece on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
5 hours ago
- News18
Rainbow Children's Medicare to acquire 76 pc stake in Pratiksha Hospital
New Delhi, Aug 12 (PTI) Multi-speciality pediatric hospital chain Rainbow Children's Medicare Ltd on Tuesday said it will acquire a 76 per cent stake in Guwahati-based Pratiksha Hospital for around Rs 171 crore. The Hyderabad-based healthcare firm has inked a definitive agreement with promoters of Pratiksha Hospital for the stake buy. The transaction values Pratiksha Hospital at an enterprise valuation of Rs 171 crore, fully funded via the company's cash reserves and internal accruals, Rainbow Children's Medicare Ltd (RCML) said in a statement. RCML will acquire a 76 per cent controlling stake, while promoter Dr Sharma & his family will retain the balance share in Pratiksha Hospital, it added. Founded in 1995 by Pramod Kumar Sharma, a pioneer of IVF, minimal invasive gynaecology surgery in Northeast India, Pratiksha Hospital commenced operations in Guwahati and subsequently delivered its first IVF baby in February 1997. 'This partnership empowers us to reach a wider community and deliver top-tier pediatric and maternal care to the families of Assam and Northeast India," RCML Chairman & MD Ramesh Kancharla said. Shares of the company were trading 2.41 per cent up at Rs 1,540 apiece on BSE. PTI MSS MSS DR DR view comments First Published: August 12, 2025, 13:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
5 hours ago
- Hans India
Rainbow Children's Medicare to acquire 76 pc stake in Pratiksha Hospital
Multi-speciality pediatric hospital chain Rainbow Children's Medicare Ltd on Tuesday said it will acquire a 76 per cent stake in Guwahati-based Pratiksha Hospital for around Rs 171 crore. The Hyderabad-based healthcare firm has inked a definitive agreement with promoters of Pratiksha Hospital for the stake buy. The transaction values Pratiksha Hospital at an enterprise valuation of Rs 171 crore, fully funded via the company's cash reserves and internal accruals, Rainbow Children's Medicare Ltd (RCML) said in a statement. RCML will acquire a 76 per cent controlling stake, while promoter Dr Sharma & his family will retain the balance share in Pratiksha Hospital, it added. Founded in 1995 by Pramod Kumar Sharma, a pioneer of IVF, minimal invasive gynaecology surgery in Northeast India, Pratiksha Hospital commenced operations in Guwahati and subsequently delivered its first IVF baby in February 1997. "This partnership empowers us to reach a wider community and deliver top-tier pediatric and maternal care to the families of Assam and Northeast India," RCML Chairman & MD Ramesh Kancharla said. Shares of the company were trading 2.41 per cent up at Rs 1,540 apiece on BSE.
The Hindu
19 hours ago
- The Hindu
Zydus gets U.S. FDA nod for Diltiazem Hydrochloride tablets
Generic drugmaker Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for Diltiazem Hydrochloride tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. A generic of Cardizem Tablets, the drug is indicated for management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride tablets had annual sales of $13.9 million in the U.S., Zydus said, citing IQVIA MAT June 2025 numbers. The approved drug will be produced at its plant in Baddi, Himachal Pradesh, the company said. Belonging to a class of drugs called calcium-channel blockers, Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle, it said. Zydus Lifesciences shares closed 2.18% higher at ₹955.90 apiece on the BSE.
